랜턴 파마(LTRN) 2026년 2분기 실적발표 콘퍼런스 콜: 영업손실 축소, LP-300 및 오픈 메디신 AI

핵심 요약

• 연구개발(R&D) 비용이 42% 감소한 180만 달러를 기록함에 따라 2026 회계연도 2분기 영업손실은 전년 동기 대비 25% 줄어든 약 350만 달러를 기록했습니다.
• 순손실은 상당한 규모의 비현금성 공정가치 조정을 포함해 약 360만 달러의 워런트 관련 비용이 주로 반영되면서 약 710만 달러(주당 0.57달러)로 확대되었습니다.
• 2026년 6월 30일 기준 현금, 현금성 자산 및 매도가능증권은 총 약 740만 달러입니다. 랜턴 파마는 5월 등록 직접 공모를 통해 약 440만 달러의 총 공모 금액을 조달했습니다.
• LP-300 HARMONIC 임상시험에서 6주기를 완료한 9명의 L858R 변이 환자의 무진행 생존기간(PFS) 중앙값은 8.9개월에 달했습니다. 경영진은 해당 코호트가 여전히 소규모이며 탐색적 단계임을 강조했습니다.
• 랜턴은 미국 식품의약국(FDA)과의 C유형 미팅 이후 L858R 환자를 중심으로 LP-300 임상을 개편하고 투여 기간을 6주기에서 최대 8주기로 연장했으며 단일군 디자인으로 전환했습니다.
• 랜턴은 2026년 8월 오픈 메디신 AI(Open Medicine AI)를 별도의 100% 자회사로 설립했습니다. 이 회사는 독자적으로 자금을 조달할 계획이며, 랜턴은 자사의 신약 개발 프로그램을 위한 플랫폼 전체 접근 권한을 유지합니다.

주요 재무 데이터

2026년 6월 30일 기준 랜턴의 발행 보통주식수는 12,759,146주였습니다. 회사는 해당 분기 동안 ATM 주식 발행 프로그램을 통한 활동이 없었다고 밝혔습니다.

사업 및 영업 실적

LP-300 및 HARMONIC 임상

랜턴은 TKI 치료 후 진행된 L858R 변이 비흡연 비소세포폐암 환자를 대상으로 HARMONIC 임상 등록을 집중하고 있습니다.

6주기를 완료한 9명의 L858R 환자 중 무진행 생존기간 중앙값은 8.9개월이었으며, 5월 11일 데이터 기준일 현재 3명의 환자는 아직 병이 진행되지 않았습니다. 전체 L858R 코호트의 무진행 생존기간 중앙값은 8.4개월이었고, 위험비는 0.37, 95% 신뢰구간은 0.15~0.89였습니다.

경영진은 또한 L858R 환자의 70% 이상에서 표적 병변 감소가 나타났으며 임상적 이득률은 77%였다고 발표했습니다. 일부 반응은 2년 이상 지속되었습니다. 회사에 따르면 4주기와 6주기 간 안전성은 유사한 수준이었습니다.

FDA와의 C유형 미팅에 따라 랜턴은 투여 기간을 최대 8주기로 연장하고 효율성 제고 및 비용 절감을 위해 단일군 임상 디자인을 채택했습니다. 환자 모집은 미국과 대만에서 계속 진행될 예정입니다.

LP-184 임상 확대

유럽의약품청(EMA)은 진행성 방광암 환자를 대상으로 한 LP-184의 연구자 주도 임상 1b/2상 연구를 승인했습니다. 코펜하겐에서 진행되는 39명 규모의 이 임상은 PTGR1 과다발현 및 DNA 손상 복구 결함을 기반으로 한 이중 바이오마커 전략을 활용합니다.

FDA는 재발성 또는 불응성 삼중음성 유방암 환자를 대상으로 한 LP-184 단독요법 임상 1b/2상 연구도 승인했습니다. 랜턴은 이 연구에서 2개 용량 코호트에 걸쳐 최대 40명의 환자를 모집한 후, 사이먼 2단계 유효성 평가를 진행할 것으로 예상합니다.

랜턴은 난소암, 간암, 신장암, 갑상선암에서 PTGR1, PTPN14, ASPH를 이용한 3개 유전자 기반 환자 선별 방법에 대해 특허 허가 통지를 받았습니다.

LP-284 및 스타라이트 테라퓨틱스

LP-284는 혈액암 및 성인 연조직 육종을 대상으로 계속 진행 중입니다. 이 프로그램은 2026년 초 희귀의약품 지정을 받았습니다.

스타라이트 테라퓨틱스는 LP-184의 뇌암 적응증 적용 물질인 STAR-001 개발을 진행하고 있습니다. 랜턴은 소아 종양학 컨소시엄과 협력하여 임상 경로를 모색 중이며, 희귀 소아 뇌암에 대한 인도적 목적 치료 프로그램 옵션도 추진하고 있습니다. 스타라이트는 여전히 랜턴의 100% 자회사이며, 별도의 자금 조달을 추진할 것으로 예상됩니다.

오픈 메디신 AI

랜턴은 8월에 오픈 메디신 AI(OMAI)를 별도 법인으로 공식 설립하고 상업용 라이선스 계약을 체결했습니다. OMAI는 문헌 합성, 의약화학, 경로 분석, 데이터 큐레이션, 포트폴리오 우선순위 지정, 임상시험 개발 등 다양한 분야의 전문 에이전트를 결합한 회사의 다중 에이전트 AI 시스템을 상업적으로 운영할 수 있습니다.

오픈 메디신 AI는 현재 랜턴이 100% 지분을 소유하고 있습니다. 경영진은 OMAI 지분을 대가로 자금을 조달할 계획이며, 장기적으로는 별도 상장법인이 되는 것을 목표로 하고 있다고 밝혔습니다. 랜턴은 최대 주주 중 하나로 남아 자체 신약 개발을 위한 플랫폼 접근 권한을 완전히 유지할 것으로 예상하고 있습니다.

경영진 전망

경영진은 수정된 프로토콜에 따른 LP-300 환자 등록을 통해 향후 4~6개월 동안 미국과 대만에서 약 15~16명의 환자가 추가될 것으로 예상하고 있습니다. 기존 코호트에 대한 추가 업데이트는 2026년 말경 제공될 수 있습니다.

랜턴은 9월 중순에 플랫폼, 시장 기회, 로드맵 및 상업적 모델을 다루는 오픈 메디신 AI 전용 설명회를 개최할 계획입니다.

추가 자금 조달은 여전히 최우선 과제로 남아 있습니다. 회사는 운영 자금 확보 기간을 연장하기 위해 자금 조달, 협력 및 기타 기회를 모색할 계획이라고 밝혔습니다.

위험 요인 및 관전 포인트

• 경영진은 LP-300 L858R 결과가 통계적 유의성을 검증하도록 설계되지 않은 소규모 탐색적 코호트에서 나온 것임을 강조했습니다. 9명 환자의 무진행 생존기간 중앙값은 데이터가 축적됨에 따라 변경될 수 있습니다.
• 랜턴은 해당 분기말 기준 약 740만 달러의 현금, 현금성 자산 및 매도가능증권을 보유하고 마감했으며, 추가 자금 조달을 최우선 과제로 제시했습니다.
• 오픈 메디신 AI가 확장하고 경쟁력을 유지하기 위해서는 추가 자본이 필요합니다. 추진 중인 자금 조달 및 장기적 별도 상장은 완료된 거래가 아니라 경영진의 목표로 남아 있습니다.
• 워런트 부채 회계처리는 보고된 당기순이익 또는 순손실에 중대한 영향을 미칠 수 있습니다. 2분기 실적에는 주로 비현금성 공정가치 조정으로 인한 약 360만 달러의 워런트 관련 비용이 포함되었습니다.
• 회사의 미래 예측 진술 공시에서 강조되었듯이, 임상 개발은 임상 결과, 규제 절차 및 경쟁 상황에 지속적으로 영향을 받습니다.

애널리스트 Q&A 주요 내용

경영진은 수정된 LP-300 프로토콜에 대한 임상시험심사위원회(IRB) 승인이 모든 임상기관에서 완료되었다고 말했습니다. 8주기 프로토콜에 따라 환자 모집이 재개될 예정이며, 다음 15~16명의 환자를 통해 보다 의미 있는 반응 데이터를 얻을 수 있을 것으로 기대하고 있습니다.

오픈 메디신 AI와 관련해 경영진은 시스템 투명성, 감사 추적 기능, 기업 고객이 워크플로우를 조정할 수 있는 점을 기존 AI 신약 개발 도구와의 차별점으로 강조했습니다. 또한 대형 제약사들의 관심을 받고 있다고 보고했으나, 상업적 매출이나 고객 지표는 공개하지 않았습니다.

경영진은 사용자가 플랫폼의 전문 도구에 접근하면 사용자 지속성(engagement)이 “매우 높다”고 설명했습니다. 대형 제약사를 포함한 인지도를 높이기 위해 이메일 홍보를 확대하고 전용 접속 코드를 활용하고 있습니다.

주주 가치와 관련해 경영진은 랜턴 주주들에게 오픈 메디신 AI 주식을 배분하는 방안을 검토 중이라고 밝혔습니다. 구체적인 구조나 일정은 확정되지 않았습니다.

실적 발표 전화회의 전문

전체 실적 발표 컨퍼런스 콜 녹취록

경영진 발표

Operator

Earnings call. As a reminder, this call is being recorded, [Operator Instructions] A webcast replay of today's conference call will be available on our website at lanternpharma.com shortly after the call.

We issued a press release before market opened today, summarizing our financial results and progress across the company for the second quarter ended June 30, 2026. A copy of this release is available through our website at lanternpharma.com where you will also find a link to the slides management will be referencing on today's call.

We would like to remind everyone that remarks about future expectations, performance, estimates and prospects constitute forward-looking statements for purposes of safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Lantern Pharma cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those anticipated.

A number of factors could cause actual results to differ materially from those indicated by forward-looking statements, including results of clinical trials and the impact of competition. Additional information concerning factors that could cause actual results to differ materially from those in the forward-looking statements can be found in our annual report on Form 10-K for the year ended December 31, 2025, which is on file with the SEC and available on our website.

Forward-looking statements made on this conference call are as of today, August 14, 2026, and Lantern Pharma does not intend to update any of these forward-looking statements to reflect events or circumstances that occur after today, unless required by law. The webcast replay of the conference call and webinar will be available on Lantern's website.

On today's webcast, we have Lantern Pharma's CEO, Panna Sharma; and CFO, David Margrave. Panna will start things off with an overview of Lantern's strategy and business model and highlight recent achievements in our operations, after which, David will discuss our financial results. This will be followed by some concluding comments from Panna, and then we'll open the call for Q&A.

I'd now like to turn the call over to Panna Sharma, President and CEO of Lantern Pharma. Panna, please go ahead.

Panna Sharma

Good morning, everyone, and thank you for joining us to discuss our second quarter 2026 results. As I've said before, AI and computationally driven approaches are now becoming central to have both large and emerging biopharma companies discover and develop drugs but also how they allocate the resources and think about staffing their scientific teams.

Today, we're at an inflection point that's actually accelerating, not just for Lantern, but for how science itself will be conducted. And we are watching it happen in real trials with real patients at Lantern. The golden age of artificial intelligence and medicine isn't beginning, it's actually accelerating. And this quarter, that idea has resulted in the development of a new company, Open Medicine AI. In August, we established Open Medicine AI as a separate company with commercial licenses and agreements with Lantern in place to take the AI data models to the next level.

I'll spend some real time on that today because I think it's the most consequential structural decision we've made since starting Lantern. But let me first walk you through what got us here, a clinical signal that sharpened into a defined patient population, a signal that was actually validated in using big data, a European regulatory clearance in a challenging recurrent cancer and allowed patent on a patient selection method for one of our most valuable assets, LP-184, and an FDA-cleared trial in triple-negative breast cancer that's moving toward launch. All of these were backed by numerous observations in our trials, the LP-300 trial, the LP-184 trial and even the LP-284 trial.

What those observations were is that the mechanistic insights gained during our preclinical work actually have real-world parallels. And they could be the basis for meaningful activity in actual cancer patients. The remainder of 2026 is a defining year for Lantern Pharma and especially as we launched in '27. We've achieved clinical validation across mobile programs while establishing the foundation for our next phase of growth in both of our engines, our drug development engine and also now our AI engine.

In addition, our midyear financial results reflect highly disciplined execution with a 25% reduction in total operating expenses year-over-year, even as we advanced multiple clinical programs through key inflection points and launched an entirely new company into one of the most promising and disruptive areas of AI, Medicine.

Our AI-driven clinical pipeline now encompasses multiple drug candidates across solid tumors, blood cancers and pediatric oncology with a combined annual market potential estimated at over $15 billion.

Let's start with our Phase II program, LP-300 and the HARMONIC trial in never-smokers non-small cell lung cancer who progressed after TKI therapy. We believe there's about 400,000 to 500,000 patients diagnosed globally each year that have no specific therapy aimed at never smokers that progressed after TKI. In Asia, it's about 35% to 40-plus percent of non-small cell lung cancer cases in U.S. and Europe, it's between 15% and 20%.

In June, we reported emerging data as the May 11 cutoff, and it shows something we didn't expect to see this clearly, but the benefit of LP-300 deepens the longer patients stay on it. Among L858R patients who completed 6 cycles, median progression-free survival reached 8.9 months. That's 9 patients, 3 of them hadn't progressed at analysis. Across the full cohort of L858R patients, median PFS was 8.4 months. The hazard ratio for that group was 0.37 with a confidence interval of 0.15 to 0.89.

So that means more than -- also more than 70% of the L858R patients saw a target lesion reduction and some of the response is sustained beyond 2 years. We've had a 77% clinical benefit rate, which is phenomenal for that line of therapy. I'll be direct. These are small exploratory cohorts, not powered for statistical significance yet. And a median from 9 patients can move up or down but what makes us take it very seriously is that a COGS regression controlling for race, gender TP53 status, which is very important, confirmed L858R as an independent predictor. This is not a demographic or a statistical artifact and safety was comparable between 4 and 6 cycles with no added toxicity from longer exposure.

So a drug that helps more, the longer you stay on it without costing you more in side effects is a drug worth extending, especially where there's no other great therapy for these patients. And that's actually the science and the data behind what we did next. We have a successful Type C meeting, where no objections were raised to our key proposed amendments. We've concentrated the enrollment now on the L858R patients. These patients actually tend to do worse on current therapy regimens. That's why we also think there's a great need. We've extended the treatment from now 6 to up to 8 cycles, and we've moved into a single-arm design, which should be more efficient and less costly.

The trial continues enrolling in the U.S. and Taiwan, and we've used this data set and other observations, of course, about the future of the program in active partnering discussions.

Let's talk a little bit about LP-184 this quarter. We've made several advances, all of which were driven by data and AI leverage methodologies. First, the EMA clearance. In July, we got clearance for an investigator-initiated Phase Ib/II trial in advanced bladder cancer. This is in Copenhagen, Denmark's national referral center for urologic cancers Rigshospitalet tout. And this is with Professor Rohrberg and Pappot. They're the coordinating investigators. This will be a 39 patient trial and very uniquely on 2 biomarker or a dual biomarker strategy, one on PTGR1 overexpression and then combining that with DNA damage repair deficiency. And we're hoping to enroll patients, very importantly, that our platform has predicted should respond and more importantly, have a mechanistic basis to be held by that drug.

Second major milestone is the 184 monotherapy in relapsed or refractory triple-negative breast cancer. That will be a Phase Ib/II trial that protocol has been FDA cleared and is now moving toward launch with a number of sites. We've also applied for grants for that trial for that study as well, which we're pretty excited about. This drug targets tumors of DNA damage repair alterations, homologous recombination deficiency or a genomic loss of heterozygosity. We expect to enroll up to 40 patients across 2 dose cohorts and will follow by a Simon 2-stage efficacy [indiscernible].

Third very important is that we received a notice of allowance in July, covering our 3 gene selection where we use 3 genes, PTGR1, PTP N-14 and AS PH for selection of patients most likely to respond to LP-184. We issued a notice of allowance in 4 tumors ovarian, liver, kidney and thyroid cancer. So that's a patent on the selection logic itself, which is one of the hardest parts of this to replicate and then map that directly to an incredible therapeutic intervention, where safety is known and mechanism is beginning to be more and more observable. This all built on our 63 patient trial that we did for 184. And now that we have a dose of 0.39 mg per kg and very importantly, what we saw in that trial is that we saw tumor reduction in patients that were carrying these DNA repair deficiency genes, CHEK2, ATM, BRCA 1, STK11, KEAP1. Those alterations conferred exceptional sensitivity to the drug.

Unlike conventional chemotherapies and other DNA damaging agents that indiscriminately target defining cells both LP-184 and 284 exploit specific genomic vulnerabilities in cancer cells. And that precision is a thread that runs parallel to both programs and which we expect to give our programs a meaningful advantage in their development. LP-284 continues in hematologic malignancies and in adult soft tissue cercocomas, where we've got orphan designation earlier this year. And Starlight briefly on the science, STAR-001, which is LP-184 in brain cancers. Our RADR platform identified that those particular brain tumors would be very sensitive if ERCC 3 was removed as a protein because that's involved in the repair mechanism.

Well, what we did is we characterize that with our group at Johns Hopkins that we collaborate with. And we're using spironolacton, which is already well characterized, safe and pediatric and adults. And it actually does exactly that. It degrades the ERCC3 protein and shuts down the repair route. And we've had great preclinical data, and now we're taking that into the clinic. We're taking it into disease designations where we have orphan designation and also rare pediatric such as ATRT, hepatoblastema, rhabdomyosarcoma and malignant rapidoid tumors. Bear in mind that each of these is independently eligible for a priority review voucher upon approval, and they recently transferred for $150 million to $200 million or more, and Lantern holds 4 of those.

On the pediatric program specifically, I'm very excited, and I want to give you an update. We're actively working with several pediatric oncology consortia to determine the best and most expeded path to bring these into a trial. As soon as possible. We've got 2 consortia that we're working with, and we'll have more data in this coming quarter.

We're also working closely to enable compassionate use for the drug, especially in some of these rare pediatric brain tumors where there's an exceptional need. Again, Starlight is 100% owned by Lantern. We expect to raise additional funding for it as a separate funding, holds its own INDs down, its own regulatory designations. And it's not just a program status. It's actually a way to monetize it independently of the rest of Lantern. And more importantly, it's a template. We're about to use that same template again this time with the underlying platform itself.

Now going back to Open Medicine. And this is, we believe, the structural news of the quarter. In August, we formally established Open Medicine, OMAI as a separate company, executed our Board-approved commercial licensing agreements. And more importantly, OMAI now can operate the multi-genic AICOscientists that we launched as with Zeta and use it in the commercial setting.

Here's the logic. Most people using AI drug development today, ask one model a question and get an answer. We now see that things are moving well beyond a single line of questioning for query. So we've built and orchestrated system. And this orchestra brings together specialized agents for literature synthesis, medicinal chemistry, pathway analysis, data curation, literature analysis, portfolio prioritization, clinical trial development and that -- then they challenge each other, and they pass information and ideas, and they cross-validate before delivering hardened results or ask the scientists or drug developer to get more engaged and ask them questions.

And this, we believe this multigenic non-monolithic model is really the standard infrastructure for specialized domains that are multi disciplinary, and we think it will be the standard infrastructure for drug discovery. And we think this is something that will be critical.

In addition to that, we believe that the computational biology model and the computational chemistry model that run deep and in their own large quantitative models is critical. And more importantly, it can generate publication quality results with a full audit trail. As a platform gets smarter and more users use it and data flows through it, each engagement for a user will feed the next. And this is exactly the kind of dynamic that deserved its own capital structure.

Clinical drug development and enterprise software are priced by different investors and different metrics held inside a clinical stage company, a software business may or may not get the credit for what it's worth because investors who price AI and software generally don't own clinical stage biotech and vice versa. That's the entire rationale for separating and racing forward with Open Medicine AI.

Open Medicine AI is 100% owned by Lantern today. It intends to raise capital at its own level in exchange for Open Medicine equity with the longer-term objective of becoming a separately listed company, Lantern expects to remain one of its largest shareholders.

So Lantern continues to retain the rights to the full access to the platform for our own drugs. And this changes nothing about this program's priority or timing. And we believe that the market there is much, much larger than just on early oncology companies like ourselves. Analysts project the market to reach about $10 billion by 2030, 2031. It was oncology is one of its largest segments.

Even doing my own bottoms-up analysis on companies in drug discovery, drug discovery technology, AI-enabled, I expect it to easily reach $9 billion to $10-plus billion by 2031. We'll host a dedicated informational call in mid-September on Open Medicine AI's market opportunity, platform, road map, commercial model. But putting all this together, a clinically validated platform with drugs and trials, a commercially accessible AI platform and software company with models and state-of-the-art tools and a drug pipeline that these all feed each other. You get a business model that extends well beyond just the clinical assets. We think it's a very powerful complement to have both of these engines, an AI engine that can be separated and power dozens of companies and drug assets that are going after meaningful, challenging rare and aggressive diseases. And we think these are very complementary.

The AI tools and services, we think can grow to being several hundred million dollars in stand-alone as part of this larger $10 billion market. We think a nice chunk of that $10 billion market will be agentic in nature, and Open Medicine will have the real chance at driving a significant piece of that. So these are 2 great growth engines in the company.

And I'll let David talk a little bit -- David Margrave, to discuss our financials or key metrics and also dig into the details behind the noncash expenses that are related to warrants that drive a higher net operating loss than what's actually underneath the hood.

So David, I'll turn it over to you.

David Margrave

Thank you, Panna, and good morning, everyone. I'll now share some financial highlights from our second quarter ended June 30, 2026. Before getting into the details of the quarter, I want to note that this quarter was different from prior quarters because we had a substantial noncash expense related to the issuance of warrants in connection with our May financing transaction and the way those warrants are treated for accounting purposes. I'll discuss this topic in detail later in my discussion.

Cash, cash equivalents and marketable securities were approximately $7.4 million at June 30, '26, consisting of approximately $6.7 million in cash and cash equivalents and approximately $0.7 million in marketable securities compared to approximately $10.1 million in cash, cash equivalents and marketable securities as of December 31, 2025.

Funding received during the second quarter of 2026 consisted of approximately $4.4 million in gross proceeds from our registered direct offering that closed on May 14, 2026. Additional funding is a top priority, and we intend to pursue additional capital raises, collaborations and other opportunities to extend our operating runway.

R&D expenses were approximately $1.8 million for the 3 months ended June 30, 2026 compared to approximately $3.1 million for the 3 months ended June 30, 2025. This was a decrease of approximately $1.3 million or 42%. The decrease was primarily attributable to reductions of approximately $1 million in research studies and materials expenses relating to the conduct of our clinical trials and decreases of approximately $0.3 million in salaries and benefit expenses.

G&A expenses were approximately $1.7 million for the 3 months ended June 30, 2026 compared to approximately $1.6 million for the 3 months ended June 30, 2025. This was an increase of approximately $0.13 million or 8%. The increase was primarily attributable to increases in business development and investor relations expenses of approximately $0.36 million and salaries and benefit expense increases of approximately $0.14 million, offset in part by decreases in other professional fees of approximately $0.35 million.

Loss from operations was approximately $3.5 million for the 3 months ended June 30, 2026 compared to a loss from operations of approximately $4.7 million for the 3 months ended June 30, 2025, representing a decrease of approximately 25%.

In connection with our May 2026 registered direct offering, in which we raised approximately $4.4 million in gross proceeds, the company issued investor warrants to purchase up to 2,135,923 shares of common stock at an exercise price of $2.27 per share and placement agent warrants to purchase up to 106,796 shares of common stock at an exercise price of $2.75 million per share. These warrants are accounted for as liabilities due to a settlement feature that may be triggered in the event of a fundamental transaction.

During the 3 months ended June 30, 2026, the company recorded an aggregate of approximately $3.6 million of expense related to these warrants. The main component of this was noncash expense arising from an increase in the fair value of the warrants that was driven primarily by a substantial increase in the company's stock price between the May 14, 2026 warrant issuance date and June 30, 2026. Other components related to warrant expense were loss on issuance of the warrants and warrant issuance costs. After including the noncash and other items related to warrants our net loss was approximately $7.1 million or $0.57 per share for the 3 months ended June 30, 2026 compared to a net loss of approximately $4.3 million or $0.40 per share for the 3 months ended June 30, 2025.

For the 6 months ended June 30, 2026, our net loss was approximately $10.4 million or $0.88 per share compared to a net loss of approximately $8.9 million or $0.82 per share for the 6 months ended June 30, 2025.

From a capitalization standpoint, as of June 30, 2026, the company had 12,759,146 shares of common stock outstanding. And as we described, in May 26, we closed a registered direct offering and concurrent private placement, comprising 1,454,175 shares of common stock, prefunded warrants to purchase up to 681,748 shares of common stock, investor warrants to purchase up to 2,135,923 shares of common stock at an exercise price of $2.27 per share and placement agent warrants to purchase up to 106,796 shares of common stock at an exercise price of $2.55 per share. There was no activity under our ATM sales facility during the 3 months ended June 30, 2026. I'll now turn the call back over to Panna for an additional update on our programs and operations. Panna

Panna Sharma

Thank you, David. So 2 closing points. First, the number I want all of you to remember is that we advanced programs from AI-derived in science to first-in-human clinical trials in a time line under 3 years and roughly 2 to 3 years at approximately $2 million to $3 million each. The industry norm to reach that same point and is 5 to 10 years is at 25 to 100. We have 3 molecules in clinical trials of dosed over 100 patients and at the same time, have been able to advance an AI platform that's launching commercially. Those numbers are not a marketing claim. It's actually our operating model, and it's a key part of our core advantage. Secondly, what we now have structurally that we didn't have just in April is a lung cancer trial refined around a specific patient population, L858R mutations. We have European clearance for a dual biomarker trial, which will be led by investigators in Denmark and a challenging recurrent bladder cancer setting. And FDA cleared a second trial in triple-negative breast cancer post-PARP refractory patients moving toward launch and an AI and software company with executed licenses, multiple engineering centers and a growing user base. As David just walked you through, we actually did all that, while our actual operating losses or loss from operations were down approximately 25% year-over-year. And we did all of this while continuing to advance both engines of growth. We believe that's a really important and smart way to build, and that's the argument for continuing to operate this way. We're not just building better tools. We're reimagining what's possible in precision oncology and building the tools to support it. We believe this will be the standard for the rest of the industry. And more importantly, it's the platform that we think will be positioned to scale. I want to thank our team, our investigators and our shareholders as we light our way through precision oncology solutions, and we expect to have a lot of great additional results over the coming quarters. And I want to especially thank our own team here at Lantern PAUSE especially a longtime member of our team, who's moving on to a new leadership opportunity in media and technology after 5 years with us. PAUSE Five years of building this company's brand, voice communications and also being an amazing colleague. So thank you very much. With that, I'd like to now open the call to questions. You can type your question using the QA tool, or raise your hand, and we'll try to unmute your line and repeat your question. So any questions with the remaining time that we have.

Operator

Michael should be unmuted. PAUSE SP578731125 Can you hear me? PAUSE. Yes. PAUSE SP-2 Two questions, Panna. -- 1 on LP-300 and then the other on OMI. Just on 300 PAUSE -- can you talk about what -- where are you in the data analysis? It's obviously nice to see the PFS stretching a little bit more. But how PAUSE matures this data set? Will it mature further? When do you plan to update us again? And any other PAUSE well, and then the next question related to that is now that you've got the protocol amendment in place, have any patients been PAUSE enrolled under the new protocol. PAUSE. All right. Let's go a lot of questions. But we -- once we got the product -- once we had sufficient confidence that the protocol would be I mean it in the data was trending that way.

We wanted to get the new IRBs approved at all the sites, and that's all been done now. So we expect enrollment to resume under the new 8 cycles, which is important. We think that will extend durability and maybe even deep in response. So we expect to be enrolling patients in Taiwan to the U.S., specifically under the new amended protocol. We hope to expect another 15, 16 patients that will give us meaningful data, and we expect to enroll those over the next 4 to 6 months, both in the U.S. and Taiwan. That's the initial focus.

질의응답

Unknown Analyst

Will there be any other updates coming on the current cohort?

Panna Sharma

We may have an update toward the end of the year. I mean, I think other than just extending PFS PAUSE we're really relying on the next batch of patients coming in to see what we would kind of responses that we continue getting.

Unknown Analyst

Okay. Very good. And then just on open medicine. Can you talk about -- I think most of us that come from sort of therapeutics background or not, experts. Most of the technology is a black box because the companies like in silico medicine and others don't open their mono to see what's actually operating internally. Maybe you can help us understand what your system looks like or how it compares, how should we think about it in the context of the other tools that are out there that the pharma industry seems to be taking advantage of.

Panna Sharma

Yes. So there's actually been working on something for our mid-September webinar, but the AI cycle in drug development, we're kind of on our fourth cycle. I mean if you go back to early days of supercomputers and molecular modeling and large installed bases was kind of like the first wave limited limited compute resource, but infrastructure heavy. We're almost at the opposite end of that now, where we have almost limitless compute resource and infrastructure install super light. And there are 2 ways caught in between that. And we really didn't have the capability to kind of get the transparency that you would want real time until after an algorithm was run.

And oftentimes, those algorithms would take days or weekends or long term. But now those can be done in seconds. And so you can get real-time what is the process that happened. We also didn't have the software and tools to do large-scale algorithm mapping and analysis because it was just extra overhead. But now we have the ability to do that. So we get transparency that we didn't have that was a luxury in the past. Now it's commonplace and people expect it. And so a lot of the large-scale AI providers, including the anthropics and open AIs of the world, and even to some extent, KEMET and Deep Seek have made some levels of transparency to how the system operates more expected. PAUSE And that is something that we rest on the shoulders of. We can do it very differently. And so that's a platform that we've built.

And more importantly, what you see it's the transparency you as an enterprise user or end user, can actually tweak it and alter it, and that just didn't exist before. So yes, we're in a different way of how AI I expect -- and I'll mention this in the webinar in September is that the people who are going to be hit the hardest are going to be 2. Number one, people who provide professional knowledge labor basically. And then second, it's going to be the existing installed base of software providers into pharma. Those days of going in being able to charge $100,000, $500,000, $300,000 for some very, very specific functionality of an installed base. Those days are going to be gone. They're all going to go to providers like open medicine. And also, you're not going to hire teams of buying from aticians and teams of data analytics people. It's just we can do all that now in the cloud with 1 smart engineer, data science person. And you can launch swarms of people, swarms of agents doing this work for you, and that's especially what we've proven with open medicine.

So I think that's the future. And I think that's where leading-edge providers like Cloud Science and others are going toward. People are going to expect greater transparency. And if you really want to democratize the development of drugs, you're going to have to be able to allow people to go to a URL to go to an app and start their inquiry. And that's exactly what we see open medicine playing is a new category that just hasn't been valued in price. I'm writing a piece you'll see by mid-September, and it's called the deflation of discovery and the birth of a new category. And that specifically talks to Agentic AI and drug development and drug discovery.

Another question. I'll take -- sorry -- so someone's asking an interest with data from large pharma. The quick answer is, yes, we've got a lot of pharma companies, both biologic groups as whether it's small molecule groups. We've had some -- had several calls with us, some visit. So the answer is yes. Large pharma is definitely interested. This is something that they're all evaluating cutting deals on looking at and large pharma will have to partner with Agentic AI to make it commonplace. I mean it's transforming the economics of early development and also late-stage development.

So yes, very much increasing interest. The more marketing, more dollars we can put behind driving awareness of open medicine and with Zeta, the more I expect. The one thing that we've seen that has been solid is that once we put the tool in front of people, it gets very sticky. So yes, thank you. Take another important question.

Let's see if we can do this one live. We're trying to live I don't know go ahead and get to live. I can also we don't want to do it live.

I can read it also if you don't want to do it live.

So this is another question. is our models, we expect will be standards in computational biology and drug development. What are you doing to ensure that and that other competitors don't copy your methods? Well, I -- first of all, everyone will copy one or another. And that's part of putting open medicine separately is to allow it to move faster, further and have its own independent balance sheet. To ensure that you always stay 1 or 2 steps ahead. Companies -- there are definitely companies that have more capital, more capital doesn't necessarily mean you're going to be the surviving entity. You can look at any industry and capital efficiency is important long term, which we've proven to be very capital efficient at. We're at a point where it needs to be a separate entity and raise its own capital to stay ahead of the curve.

The things that we're doing in addition to continuing to train our models and try to grow intelligently using our center in Bangalore, India. Those are things that we're doing. We're also constantly benchmarking like we did with our BBB algorithm like we're doing with our bio computational tools. We're trying to pick some of the toughest challenges and go deep as opposed to go abroad. And that's one of the things that were big components of is going deep in certain categories versus broad across all of science. I don't think we ever would have claimed, hey, we're going to be cloud science and do all of science. I think that just makes no sense to me.

You can pick specific categories like rare cancers, specific areas like biocomputational tools, specific problems like blood brain barrier or penetration into any tissue type and do it and resolve it really, really well. So we're going to go after certain diseases that we think require that kind of depth and then march forward in that fashion. But yes, capital, no doubt, more capital is needed to drive that.

Let's go ahead and get to the next question. Yes, let's go to Baird and Red ship team. Maybe we can answer that 1 live Bard and Red ship team, if you guys want to ask your question live. They can ask their question live. You have to read the question.

Okay. All right. Dave, asking a question on what does adoption and feedback look like? The adoption is very sticky. Like I said before, once we get it in front of users. We were taking certain measures to make sure that users get the benefit of the full platform. We've introduced a new code called Wood Zeta 14 that people can sign up for and get the full professional addition, people who play the professional edition, specially generative chemistry, biocomputational tools, the investigator mode, it tends to be very, very sticky. So that's exciting news. Key is getting them to that point. So we're also beginning to implement some more aggressive e-mail campaigns to drive the awareness and specialized codes for certain larger pharma companies. But yes, great question. Okay. Another question is

Anonymous. What would you contemplate the biggest benefit of the open medicine spin-out will be for shareholders?

Well, Lantern owns 100% of open medicine today. We think it's poised to be very disruptive, disruptive companies are usually valued -- can be valued higher, and we're going to raise capital. Matter will continue being the largest shareholder, we think, for a while. PAUSE -- and we may explore ways to distribute those -- the underlying shares to all shareholders and lanterns. So those are things that we're talking about and potentially distribution of the shares of open medicine to all Lantern shareholders. Again, we're having discussions. We're looking at the most efficient ways to do that, but I expect Lantern shareholders to continue being beneficiaries of that asset as we monetize it, both in private financings and very importantly, as it potentially goes into an exchange public exchange.

Okay. I think we're coming up to almost 45 minutes into the call. And we look forward to answering questions and one-on-ones as it continues. I know we have a couple of requests for some one-on-one follow-up meetings. We'll take those as well. And thank you, guys, for participating. I want to thank all the Lantern investors, people who are interested, and I look forward to giving you guys more updates as the year continues. Thank you, and thank you again to our team as well.

David Margrave

Thanks a lot.